HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 35, 32419-32422, August 31, 2001

This Article Full Text Full Text (PDF) All Versions of this Article: 276/35/32419    most recent C100299200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, X.-J. Articles by Ling, N. Search for Related Content PubMed PubMed Citation Articles by Liu, X.-J. Articles by Ling, N.

ACCELERATED PUBLICATION
Identification of a Nonpeptide Ligand That Releases Bioactive Insulin-like Growth Factor-I from Its Binding Protein Complex^*

Xin-Jin Liu, Qui Xie, Yun-Fei Zhu^§, Chen Chen^§, and Nicholas Ling^¶

From the Department of  Peptide Chemistry and ^§ Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, California 92121

Insulin-like growth factor-I (IGF-I) has both metabolic and mitogenic activities mediated through interaction with the type 1 IGF receptor. The circulation of IGF-I in blood and interstitial fluid is not free but bound mostly to a family of six high affinity IGF-binding proteins, which form stable complexes with IGF and neutralize its bioactivity. Therefore, displacement of this large pool of endogenous IGF from the binding proteins could elevate "free" IGF levels to elicit beneficial effects in diabetes and other IGF-responsive diseases comparable with those produced by administration of exogenous IGF-I. We report here the identification of a nonpeptide ligand NBI-31772, which displaces IGF-I from all six IGF-binding proteins at low nanomolar concentrations from screening of the in-house chemical libraries. Furthermore, the released free IGF-I was shown to be biologically active in an in vitro bioassay. Thus, NBI-31772 could serve as a valuable lead molecule for the design of novel therapeutics to treat diabetes and other IGF-responsive diseases.

This article has been cited by other articles:

				J. D. Schertzer, S. M. Gehrig, J. G. Ryall, and G. S. Lynch Modulation of Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein Interactions Enhances Skeletal Muscle Regeneration and Ameliorates the Dystrophic Pathology in mdx Mice Am. J. Pathol., October 1, 2007; 171(4): 1180 - 1188. [Abstract] [Full Text] [PDF]